Plasmodium falciparum Phospholipase C Hydrolyzing Sphingomyelin and Lysocholinephospholipids Is a Possible Target for Malaria Chemotherapy

Kentaro Hanada,1,2 Nirianne Marie Q. Palacpac,3 Pamela A. Magistrado,3 Ken Kurokawa,4 Ganesh Rai,3 Daiji Sakata,1 Tomoko Hara,2 Toshihiro Horii,3 Masahiro Nishijima,1 and Toshihide Mitamura3

1Department of Biochemistry and Cell Biology, and 2CREST, Japan Science and Technology Corporation, National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
3Department of Molecular Protozoology, Research Institute for Microbial Diseases, and 4Genome Information Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan

Abstract

Sphingomyelinase (SMase) is one of the principal enzymes in sphingomyelin (SM) metabolism. Here, we identified a Plasmodium falciparum gene (PfNSM) encoding a 46-kD protein, the amino acid sequence of which is ~25% identical to that of bacteria SMases. Biochemical analyses of the recombinant protein GST-PfNSM, a fusion protein of the PfNSM product with glutathione-S-transferase, reveal that this enzyme retained similar characteristics in various aspects to SMase detected in P. falciparum–infected erythrocytes and isolated parasites. In addition, the recombinant protein retains hydrolyzing activity not only of SM but also of lysocholinephospholipids (LCPL) including lysophosphatidylcholine and lysoplatelet-activating factor, indicating that PfNSM encodes SM/LCPL-phospholipase C (PLC). Scyphostatin inhibited SM/LCPL-PLC activities of the PfNSM product as well as the intraerythrocytic proliferation of P. falciparum in a dose-dependent manner with ID50 values for SM/LCPL-PLC activities and the parasite growth at 3–5 μM and ~7 μM, respectively. Morphological analysis demonstrated most severe impairment in the intraerythrocytic development with the addition of scyphostatin at trophozoite stage than at ring or schizont stages, suggesting its effect specifically on the stage progression from trophozoite to schizont, coinciding with the active transcription of PfNSM gene.

Key words: lysophosphatidylcholine • lysoplatelet-activating factor • sphingosylphosphocholine • sphingomyelinase • intraerythrocytic stage

Introduction

Malaria remains a devastating disease worldwide, especially in the tropics. Plasmodium falciparum, the deadliest among four species of malaria parasites that infect humans, is responsible for more than a million deaths annually. Emergence and spread of resistant parasites to agents such as chloroquine and pyrimethamine/sulfadoxine highlights the need to develop new drugs against this disease. In this quest, elucidating the differences in metabolisms between host and parasite at the molecular level would provide novel targets for malaria chemotherapy.

Lipid metabolism, which is almost nonfunctional in uninfected erythrocytes (1), rises drastically during intraerythrocytic development of malaria parasites (2, 3) contributing mainly to membrane biogenesis. Membrane biogenesis includes not only organelle membranes of proliferating parasites but also the tubovesicular membrane network in the cytoplasm of infected erythrocytes (2, 4). The parasites meet the demand for the necessary lipid species by synthesizing through de novo pathways as well as acquiring from extracellular sources (2, 5, 6). parasite cells, therefore, appear to develop unique features in lipid metabolism for survival in the intraerythrocytic environ-
ment, prompting an increase in attention on lipid metabolism to provide rational targets for malaria chemotherapy (7–10).

Sphingolipids, which are widely distributed in eukaryotes, play important roles in the growth of cells (11–13). Sphingomyelin (SM)* is the most abundant of the mammalian sphingolipids, and degradation of SM to ceramide appears to be responsible for the modulation of various cellular events including proliferation, differentiation, and apoptosis (14–16). SM is also associated with the plasmodial parasites (2, 17); however, SM metabolism in parasite cells is poorly understood.

Sphingomyelinas (SMase) is a principal enzyme catalyzing the hydrolysis of SM to ceramide and phosphocholine (18). In mammalian cells, there are two well-known types of SMase. One is termed acid SMase, with an optimum pH at around 4.8; further subclassified to two isoforms, an endosomal/lysosomal acid SMase and a secretory Zn²⁺-dependent SMase. The other type of mammalian SMase, termed neutral SMase, is a membrane-bound and Mg²⁺-dependent SMase, with an optimum pH at around 7.5. One isoform of neutral SMase has been recently demonstrated to have substantial phospholipase C (PLC) activity toward lysocephatidylcholine (lysoPtdCho) and lysophosphatidylethanolamine (lysoPAF; reference 19). Some bacteria produce extracellular Mg²⁺-dependent neutral SMases (18) that are presumably implicated in degradation of environmental SM for nutritional use or for infection to vertebrate hosts. Several cDNAs encoding acid and neutral SMases (18, 20–23) and genes for bacterial SMase (24–26) have been identified so far. There has been no report, however, of a plasmodial SMase gene.

We have recently demonstrated that *P. falciparum*-infected human erythrocytes but not uninfected erythrocytes retain the activity of a neutral SMase (27). Here, we identify and characterize the *P. falciparum* gene encoding a neutral SMase. The enzyme encoded by the plasmodial gene retains phospholipase C activity toward lysocholine-phospholipids (LCPL) as well as SM, and this PLC activity was inhibited by scyphostatin. In addition, the effect of scyphostatin on in vitro culture of *P. falciparum* was investigated to implicate this enzyme with the intraerythrocytic development of parasite cells.

Materials and Methods

**Materials.** Bovine brain SM, sphingosylphosphocholine, phosphatidylycerine (PtdSer), PAF, lysoPAF, 1-monopalmitoyl-sn-glycerol, 1-octadecyl-s-n-glycerol, intact BSA (product no. A-1933), and fatty acid-free BSA (product no. A-7511) were purchased from Sigma-Aldrich. Fatty acid-free BSA was used as lipid-free BSA (6). Egg lysoPtdCho was from Avanti Polar Lipids, Inc., and 1-hexadecyl-2-acetyl-sn-glycerol from Biomol Research Laboratories Inc. [Choline-methyl-³⁵S]SM (55 mCi/mmol) and [cholesterol-methyl-¹⁴C]PtdCho 1-e-dipalmityl (55 mCi/mmol) were purchased from American Radiolabeled Chemicals Inc. 1-O-¹⁴C]octadecyl PAF (163 Ci/mmol), 1-O-¹³C]octadecyl lyso-PAF (163 Ci/mmol), and [8-³⁵S]-hypoxanthine (18–27 Ci/mmol) were from Amersham Pharmacia Biotech, and [palmitoyl-¹-¹⁴C]lysoPtdCho 1-1-monopalmitoyl (55 mCi/mmol) from NEN Life Science Products. Scyphostatin was generously provided from Sankyo Co. and d, l-threo-1-phenyl-2-hexadecanoylamino-3-morphiolino-1-propanol (PPMP) was from Matrey, Inc. Scyphostatin and PPMP were dissolved in DMSO at 10 mM and stored at −20°C until use. PF1350, a *P. falciparum* expression sequence tag (EST) clone, was generously provided by Dr. Debopam Chakrabarti (University of Central Florida, Orlando, FL).

**Parasite Culture.** *P. falciparum* parasite lines used are 3D7, Honduras-1 (6), Dd2 (28), HB3 (28), and FCR3 (29). 3D7 line was a generous gift from Dr. Masatusugi Kinura (Osaka City University, Osaka, Japan). HB3 and Dd2 lines were provided by Dr. Thomas E. Wellems (National Institutes of Health, Bethesda, MD). Parasite cells were routinely maintained as described previously (6, 27).

$^{3}P$-Rapid Amplification of cDNA Ends. Parasite cells were isolated from the asynchronous culture of 3D7 line through 0.075% saponin/PBS (wt/vol) treatment. Total RNA was extracted from isolated parasites with Trizol (GIBCO BRL). First strand cDNA was synthesized from 200 ng total RNA with SMART™-Rapid Amplification of cDNA Ends (RACE) cDNA Amplification Kit (CLONTECH Laboratories, Inc.) by using the Script II reverse transcriptase (GIBCO BRL). PCR was conducted with Platinum™ Taq polymerase High Fidelity (GIBCO BRL) using the following conditions in a Peltier Thermal Cycler–200 (MJ Research, Inc.): one initial denaturation cycle at 94°C for 1 min, 10 cycles of denaturation at 94°C for 20 s, annealing and extension at 62°C for 5 min, 1 cycle of extension at 72°C for 10 min proceeded by 35 cycles at 91°C for 20 s, and at 70°C for 5 min, with a final extension cycle at 68°C for 10 min. The gene specific primer, 5'-GGGCTCTTGATATGGCGACCTATTAC-3', was used together with universal primers provided in SMART™ RACE cDNA Amplification Kit.

**Northern Blotting.** Total RNA was extracted from parasite cells isolated from asynchronous cultures of 3D7, Honduras-1 and Dd2, or synchronized culture of HB3. For the harvest of ring-rich or trophozoite- and schizont-rich parasite cultures, tightly synchronized culture of HB3 line within 4 h life span (6) was further incubated for 12 or 27 h, respectively, and parasite cells were then isolated by saponin treatment. Extracted total RNA was fractionated on a 1.2% agarose/formaldehyde gel and transferred onto Nytran membrane (Schleicher & Schuell). The membrane was probed with a 744-bp PCR product encoding the internal region of PfNSM open reading frame (ORF), exposed to Fujifilm BAS imaging plate, and analyzed with MacBAS 1500 (Fuji Film Co.). For probe preparation, 5'-CCACA-CAATGTTATTAGGTCCG-3' and 5'-GTGTATATATATAATCCTTTTCG-3' were used for PCR as forward and reverse primer, respectively.

**Reverse Transcription PCR.** Total RNA was extracted from parasite cells isolated from a synchronized culture of Honduras-1 line. Tightly synchronized culture of Honduras-1 line within 4 h life span was further incubated for 1, 20, 25, 30, or 36 h before saponin treatment. Reverse transcription (RT)-PCR was conducted with GIBCO BRL Superscript™ First-strand Synthesis System for RT-PCR using 50 ng total RNA. Target cDNA was
amplified by the same set of primers used for probe preparation. For control, primer sets that annealed to the conserved block 3 and 5 of merozoite surface antigen-1 gene (30) were used: 5'-TTCCGTGCAATGGAATTAGCCTAC-3' (forward primer) and 5'-GGATCATGAAATTTAAATCACATGTG-3' (reverse primer). RNA samples from the different stages that were not treated with reverse transcriptase gave no PCR products.

Plasmid Constructs. PF1530C is a \textit{P. falciparum} cDNA cloned in pBluescript\textsuperscript{®} SK (31). For construction of PfNSM, ATGC-CAAGAATAG sequence was added to 5' terminus of PF1530C by PCR with PF1530C as template DNA, 5'-TAAGGATCCGCCACCATGCAAGAATTAAATCACAAAGATGT-AAAGC-3' as forward primer, and 5'-TAAATGTACTAGGAATTCC-3' as reverse primer. The amplified fragment was digested with BamHI and EcoRI, and the resulting 0.8 kb fragment was ligated to a BamHI- and EcoRI-digested 3.7 kb fragment from the PF1530C on pBluescript\textsuperscript{®} SK.

The pGEX-PfNSM was constructed from a BamHI- and Xhol-digested 1.7 kbp fragment from pGEX-6P-2 (Amersham Pharmacia Biotech), with the resulting plasmid encoding a fusion protein of multi-cloning sites of pGEX-6P-2. Hereafter, manipulations were performed at 4°C or on ice. Cells harvested by centrifugation, washed with 20 ml of 10 mM Tris-HCl (pH 8.0) containing 0.1 M NaCl and 1 mM EDTA, and suspended with 10 ml of 25 mM Tris-HCl (pH 8.0) containing 50 mM glucose and 10 mM EDTA. Egg white lysozyme was added to the cell suspension at a final concentration of 100 \( \mu \)g/ml, and the mixture was incubated for 10 min. After addition of 10 ml HSEI buffer (10 mM Hepes-NaOH [pH 7.5] containing 0.25 M sucrose, 1 mM EDTA, and a protease inhibitor cocktail [EDTA-free Complete\textsuperscript{TM} Protease Inhibitor; Roche]), the resulting mixture was sonicated five times with a probe-type sonicator at 20 W for 10 s. The sonicated sample was centrifuged (1500 g, 15 min), and the supernatant fluid was recovered as cell lysate. Cell lysate was centrifuged (15,000 \( \times \) g, 1 h), and the recovered supernatant and precipitated fractions were designated as cytosol and membrane fractions, respectively. The precipitated membranes were suspended in HSEI buffer. Fractions were stored at \(-80^\circ\)C.

Assays of PLC Activities toward Various Phospholipids. Assay of neutral SMase dependent on Mg\(^{2+}\) and PtdSer was routinely performed under detergent-mixed micelle conditions as described previously (27). In brief, enzyme sources were incubated in 50 \( \mu \)l of 50 mM Hepes-NaOH (pH 7.5) containing 10 mM MgCl\(_2\), 1 mM bovine brain PtdSer, 0.1% Triton X-100, 0.2% \( \beta \)-octylglycoside, and 10 \( \mu \)M [\textit{choline}-methyl-\( ^{14} \)C]SM at 37°C for 30 min. Reaction was stopped by addition of 0.8 ml chloroform/methanol (2/1, vol/vol). After phase separation, the radioactivity partitioned to the upper aqueous phase was measured. For PtdCho-PLC assay, 10 \( \mu \)M [\textit{choline}-methyl-\( ^{14} \)C]PtdCho in place of [\textit{choline}-methyl-\( ^{14} \)C]SM was used as a substrate. Under detergent-free assay condition, radioactive SM or PtdCho was dispersed in deionized water with a probe-type sonicator before use.

For other PLC assays, enzymatic reaction was proceeded under detergent-free condition using 10 \( \mu \)M corresponding radioactive substrate, 1-1-\([\textit{palmitoyl}]\)\(-^{1}\)H]lysoPtdCho, 1-O-\([\textit{H}]\)octadecyl PAF or 1-O-\([\textit{H}]\)octadecyl lypoPAF. During the phase separation, 20 \( \mu \)l monopalmitoylglycerol, 1-hexadecyl-2-acetyl-glycerol or 1-octadecyl-\( \alpha \)-glycerol (1 mg/ml each in chloroform) was added as a carrier. Lipids recovered in organic phase were developed on TLC with a solvent system of diethyl ether/acetate (200/1, vol/vol), and separated radioactive lipids were analyzed with a BAS2000 or BAS1800 image analyzer, followed by radioactive measurements of corresponding product with liquid scintillation counter. In all PLC assays described above, background activities from the enzyme-free controls, in which vehicle buffers instead of the enzyme sources were added, were routinely subtracted from the activities of samples containing enzyme sources.

Growth Inhibition of \textit{P. falciparum} Cell Lines. In vitro susceptibility of \textit{P. falciparum} lines to compounds tested was determined by \([\textit{H}]\)hypoxanthine uptake assay (32) using either a modified standard medium or a serum-free medium supplemented with various concentrations of the test compounds. The modified standard medium is a basic medium (27) without hypoxanthine containing 10% human serum, whereas the serum-free medium was prepared as follows: lipid-free BSA powder was dissolved in a hypoxanthine-free basic medium to adjust to 30 \( \mu \)M, and then supplemented with 7.4 mM hypoxanthine and 600 \( \mu \)M intact BSA solutions (6) at 0.1% and 10% (vol/vol), respectively. Parasite cultures synchronized to ring stage with 5% d-sorbitol (33) was adjusted to \( \sim \)0.5% parasitemia at 3% hematocrit in 100 \( \mu \)l volume per well. After 24 h incubation, 25 \( \mu \)l of either medium containing 20 \( \mu \)Ci \([\textit{H}]\)hypoxanthine was added into each well and the culture was incubated for another 24 h before harvesting. The parasitemia was also determined microscopically (6).

Effect of Compounds on the Intraerythrocytic Development of \textit{P. falciparum}. A tightly synchronized culture of \textit{P. falciparum} Honduras-1 line within 4 h life span was prepared, and adjusted to \( \sim \)1% rings at 3% hematocrit in the modified serum-free medium with 370 \( \mu \)M hypoxanthine and 0.1% DMSO. At the time indicated, the medium was replaced with prewarmed medium containing either 1 \( \mu \)M scyphostatin or 5 \( \mu \)M PPMP in place of 0.1% DMSO and the parasite culture was maintained until 52 h. Giemsa-stained thin-blood smears were prepared from the culture at various times. To prevent nutrient deprivation, the medium was changed every 12 h.

Miscellaneous. Anti-PfNSMase antisera was prepared by immunization of rabbits with synthetic peptides corresponding to the 134–152th amino acid residues of PfNSMase which were conjugated with KLH, and then the anti-PfNSMase antibodies were purified by affinity chromatography with an antigen peptide-linked resin. Western blotting was performed using the rabbit anti-PfNSMase antibodies as the primary antibody and horseradish peroxidase-conjugated goat anti-rabbit IgG (Pierce Chemical Co.) as the secondary antibody, and visualized with an ECL Kit (Amersham Pharmacia Biotech). Membrane fraction from the \textit{P. falciparum} parasite and bovine brain was prepared as described previously (27). Protein concentrations were determined by the method of Lowry et al. (34), using BSA as the standard.

Results

Identification of PfNSM, a Plasmodial Gene Putatively Encoding an SMase. To identify the gene for placmodial SMase, in silico sequence analysis was performed by search-
ing the NCBI Malaria Genetics and Genomics databases (http://www.ncbi.nlm.nih.gov/Malaria) through the BLAST program with the amino acid sequence of *Staphylococcus aureus* SMase (GenBank/EMBL/DDBJ accession no. X13404) as a query. One EST clone PF1350C (GenBank/EMBL/DDBJ accession no. N97823) and DNA contig fragment (GenBank/EMBL/DDBJ accession no. AC005505) in chromosome 12 of *P. falciparum* was found to encode a candidate gene for SMase. DNA sequence of the 1.7 kbp PF1350C clone matches the corresponding genomic sequence perfectly except for the poly(A) tail. However, comparison of the genome and PF1350C sequences suggested that the longest ORF encoded in PF1350C was not full-length, because there is a Met codon in the genomic sequence at 13 bp upstream of the 5’ terminus of the ORF. To know the structure of the full-length ORF, we performed 5’ -RACE experiment by using the 3D7 line of *P. falciparum* as RNA source. Taken together, the 2.18 kbp cDNA sequence reconstituted from PF1350C and the 5’ -RACE product was regarded as a cDNA encoding the full-length ORF (GenBank/EMBL/DDBJ accession no. AF323591). For simplicity, we refer to the locus in the genomic DNA encoding this cDNA as the *PfNSM*. Sequence analysis of *PfNSM* and its cDNA predicts that *PfNSM* is an intronless gene.

![Figure 1](image)

**Figure 1.** Primary structure of *P. falciparum* SM/LCPL-PLC. (A) Deduced amino acid sequence of *P. falciparum* SM/LCPL-PLC. (B) Hydrophathy profile of the deduced *PfNSM* product obtained using Kite-Doolittle algorithm with a window size of nineteen (reference 35). (C) Intracellular distribution of GST-PfNSMase expressed in *E. coli*. After centrifugation at 105 g for 1 h, *E. coli* cell lysates transfected with pGEX-PfNSM (lanes 1 and 2) or pGEX-PfNSM d (lanes 3 and 4), were analyzed by Western blotting using anti-PfNSMase antibodies. Lanes 1 and 3, supernatant; lanes 2 and 4, pellet fraction. 2 μg protein was loaded in each lane. (D) Multiple sequence alignment of the SMases from different species. Sequence alignments were performed with CLUSTAL W (reference 47) and refined with GeneAlign program (reference 48) using amino acid sequences in the regions where significant homology was observed through the dotplot analysis. The regions in each amino acid sequence used are PFAL (*P. falciparum*), 182–278; BCER (*B. cereus*), 129–225; SAUR (*S. aureus*), 134–230; LINT (*L. interrogans*), 179–275; HSAP1 (*H. sapiens*), 81–181; and HSAP2 (*H. sapiens*), 406–513. Amino acid residues conserved in all species and more than four species are highlighted in black and gray, respectively. (E) Phylogenetic tree of SMases. The multiple sequence alignment shown in D was used to make the phylogenetic tree through neighbor-joining algorithm with MEGA version 2.2 (reference 38). Scale bar indicates the number of substitutions per site. Bootstrap values are percentages of 1,000 replications and are shown at the nodes. GenBank/EMBL/DDBJ accession no. for each SMase is in parentheses. UPGMA also gave similar phylogenetic tree with similar topology.

![Figure 2](image)

**Figure 2.** Multiple sequence alignment of the SMases from different species. Sequence alignments were performed with CLUSTAL W (reference 47) and refined with GeneAlign program (reference 48) using amino acid sequences in the regions where significant homology was observed through the dotplot analysis. The regions in each amino acid sequence used are PFAL (*P. falciparum*), 182–278; BCER (*B. cereus*), 129–225; SAUR (*S. aureus*), 134–230; LINT (*L. interrogans*), 179–275; HSAP1 (*H. sapiens*), 81–181; and HSAP2 (*H. sapiens*), 406–513. Amino acid residues conserved in all species and more than four species are highlighted in black and gray, respectively. (E) Phylogenetic tree of SMases. The multiple sequence alignment shown in D was used to make the phylogenetic tree through neighbor-joining algorithm with MEGA version 2.2 (reference 38). Scale bar indicates the number of substitutions per site. Bootstrap values are percentages of 1,000 replications and are shown at the nodes. GenBank/EMBL/DDBJ accession no. for each SMase is in parentheses. UPGMA also gave similar phylogenetic tree with similar topology.
that encodes a protein of 393 amino acid residues (Fig. 1 A) with a molecular mass of 46,013 and has 80% A/T content typical of plasmodial genes (31).

Although SMase activity detected in isolated parasites is membrane-bound (27), hydropathy profile (35) predicts that neither signal sequence nor transmembrane region was present in the deduced PfNSM product (Fig. 1 B). Western blot analysis showed that the PfNSM product was largely associated to membrane fraction in E. coli cells when expressed as a fusion protein with GST, but that its membrane-bound nature was significantly abrogated by deletion of the 2–68th amino acid residues of the PfNSM product (Fig. 1 C). These results suggest that a moderately hydrophobic region encompassing 12–60 amino acid residues of the PfNSM product (Fig. 1 B) plays a role in the binding of this protein to membranes, although other regions might also be involved in membrane binding. Motif analysis programs, PSORT (36) and SignalP (37), predict that the PfNSM product has no cleavable signal peptide sequence.

Phylogenetic analysis conducted using MEGA version 2.2 (38) with the multiple sequence alignment (Fig. 1 D) suggests that the PfNSM sequence is more similar to SMase sequences of bacteria than those of human (Fig. 1 E), although P. falciparum is a eukaryote.

Stage-specific Expression of PfNSM. Northern blotting experiment with three different parasite lines (Honduras-1, 3D7, and Dd2) showed a single hybridized signal at 2.2 kb (Fig. 2 A), indicating that the PfNSM is indeed transcribed in intraerythrocytic parasite cells, and ubiquitously expressed in various P. falciparum strains. The 2.2 kb size detected in Northern blotting is consistent with that of the PfNSM cDNA described above.

Using a synchronized HB3 parasite line, a 2.2 kb hybridized signal was likewise detected specifically in trophozoite- and schizont-stage rich sample (Fig. 2 B) in a separate Northern blot. However, no distinct band was detected in ring-stage rich sample, though the amount of total RNA loaded was increased from 4 to 10 μg (Fig. 2 B). To further

Figure 2. Stage-specific transcription of PfNSMase in the intraerythrocytic parasite P. falciparum. (A) Northern blotting of asynchronous parasite culture. 10 μg of total RNA prepared from asynchronous cultures of three P. falciparum lines was loaded in each lane. The ethidium bromide–stained gel (lanes 1–3) shows the comparable loadings of RNA. Lane 1 and 4, 3D7; lane 2 and 5, Honduras-1; lane 3 and 6, Dd2. The position of the standard RNA marker (GIBCO BRL) is shown at the left. The stage distribution for each line is indicated: 3D7, 63% ring, 26% trophozoite, 11% schizont; Honduras-1, 71% ring, 22% trophozoite, 7% schizont; and Dd2, 48% ring, 26% trophozoite, 26% schizont. (B) Northern blotting of synchronous parasite culture. 4 μg (lanes 1, 2, 5, and 6) and 10 μg (lanes 3, 4, 7, and 8) of total RNA prepared from different stages of tightly synchronized culture of HB3 line was loaded. The ethidium bromide–stained gel (lanes 1–4) indicates the comparable loadings of RNA from the different stages at two different concentrations. Lanes 1, 3, 5, and 7, ring-rich culture (99% ring, 1% trophozoite, 0% schizont); lanes 2, 4, 6, and 8, trophozoite- and schizont-rich culture (0% ring, 86% trophozoite, 14% schizont). The position of the standard RNA marker is shown at the left. (C) RT-PCR experiment. PCR products obtained from different concentrations of first strand cDNA from various stages of tightly synchronized parasite culture of Honduras-1 line were analyzed in 0.8% agarose gel. Lanes 1 and 2, 3 and 4, 5–9, 10–14, and 15–19 are products obtained from ring, young trophozoite, mature trophozoite, schizont, and segmented-schizont, respectively. Parasite morphology at each stage used is shown on top. Dilution factors of the first strand cDNA solution are as follows: lanes 1, 2, 3, 5, 10, and 15, no dilution; lanes 4, 6, 11, and 16, 10-fold; lanes 7, 12, and 17, 100-fold; lanes 8, 13, and 18, 1,000-fold; lanes 9, 14, and 19, 10,000-fold.
specify the stage when the transcription of \( PfNSM \) occurs, we performed RT-PCR by using the total RNA from ring, young and mature trophozoite, schizont, and segmented schizont stage parasite cultures. A distinct PCR product of the expected size could be detected in the sample starting from young trophozoite stage to the later stages (Fig. 2 C). In contrast, no PCR product could be detected in the ring stage sample, although the quality and quantity of the RNA sample used was enough to amplify a control PCR product corresponding to the conserved region of merozoite surface protein-1 gene (Fig. 2 C, lane 1). The level of the PCR product for \( PfNSM \) increased as intraerythrocytic development proceeded reaching a maximum at segmented schizont stage.

Expression of \( PfNSM \) Gene in \( E. coli \). To determine whether \( PfNSM \) encodes a SMase, we constructed a recombinant plasmid designated pGEX-PfNSM, in which the coding sequence of \( PfNSM \) gene was linked to GST sequence proceeded by a bacterial expression unit. Sonicated lysates of \( E. coli \) cells transfected with pGEX-PfNSM or the empty vector pGEX-6P-2 were assayed for the activity of SM hydrolysis under various conditions (Table I). When assayed under acidic conditions, no activity was detected even in the presence of \( \text{Zn}^{2+} \), which activates an isoform of mammalian acid SMase (20). In contrast, under assay conditions for a plasmodial neutral SMase dependent on \( \text{Mg}^{2+} \) and anionic phospholipids (27), substantial activity was detected in the lysate from cells transfected with pGEX-PfNSM, but not with the empty vector. The activity of the pGEX-PfNSM-transfected cell lysate was reduced to around 1/100 when the exogenous PtdSer was omitted from the assay. Water-soluble radioactivity liberated from \([\text{choline-methyl}]^{14}\text{C}]\text{SM}\) comigrated with a standard phosphocholine in TLC (data not shown), indicating that \( PfNSM \) produces a SMase belonging to the PLC type. For simplicity, we tentatively refer to the specific products of \( PfNSM \) and pGEX-PfNSM as PfNSMase and GST-PfNSMase, respectively.

Almost 100% SMase activity in lysate of \( E. coli \) cells transfected with pGEX-PfNSM was precipitated at high-speed centrifugation. It is likely that the sedimentation of the SMase activity was due to the membrane-bound nature of this enzyme, rather than the formation of an insoluble aggregation (“inclusion body”) in \( E. coli \), because SMase activity in the precipitate fraction was efficiently solubilized by 1% Triton X-100, a nonionic mild detergent (data not shown). When the membrane fraction of \( E. coli \) expressing GST-PfNSMase was used as the enzyme source, the SMase activity was linear for at least 30 min, was directly proportional to protein concentrations up to 0.2 mg/ml, showed an apparent Michaelis constant (\( K_m \)) value for SM of \( \sim 90 \mu \text{M} \) and was \( \text{Mg}^{2+} \) dependent with a half saturation concentration of \( \sim 3 \mu \text{M} \) (data not shown).

Table I. SM Hydrolysis in Lysates of \( E. coli \) Cells Transfected with pGEX-PfNSM or the Empty Vector

| Assay conditions | Empty vector | pGEX-PfNSM |
|------------------|--------------|------------|
|                   | pGEX-PfNSM   | Empty      |
| pH 4.8           | <0.05        | <0.05      |
| pH 4.8, 10 mM ZnCl₂ | 0.061 ± 0.023 | <0.05 |
| pH 7.5, 10 mM MgCl₂ | 5.69 ± 0.29  | <0.05 |
| pH 7.5, 10 mM MgCl₂, 1 mM PtdSer | 5.69 ± 0.29 | <0.05 |

Sonicated lysates (25 \( \mu \text{g} \) protein) of \( E. coli \) cells transfected with pGEX-PfNSM or the empty vector pGEX-6P-2 were incubated with \([\text{choline-methyl}]^{14}\text{C}]\text{SM}\) in 0.1 M sodium acetate buffer (pH 4.8) containing 0.1% Triton X-100 in the presence or absence of 10 mM ZnCl₂ or in 50 mM Hepes-NaOH buffer (pH 7.5) containing 0.1% Triton X-100 and 10 mM MgCl₂ in the presence or absence of 1 mM bovine brain PtdSer at 37°C for 30 min. The water-soluble radioactivity released from \([\text{choline-methyl}]^{14}\text{C}]\text{SM}\) was measured as described under Materials and Methods. The mean values ± SD from triplicate experiments are shown.

Susceptibility of GST-PfNSMase to Scyphostatin. Previously we have shown that neutral SMase activity associated with the membrane fraction from isolated \( P. falciparum \) parasite was inhibited by scyphostatin (27), a compound that was originally found as an inhibitor of mammalian neutral SMase (39, 40). The \( PfNSM \) encodes the enzyme exhibiting PLC activity toward SM and LCPL. We tested
We then examined the effect of scyphostatin on the intraerythrocytic development of P. falciparum. To examine the effect of scyphostatin on the intraerythrocytic development of P. falciparum, we monitored the morphological changes of tightly synchronized parasites within 4 h life span, which were treated with scyphostatin at different stages. PPMP was used for comparison. Honduras-1 line was chosen as the representative parasite since all parasite lines tested so far showed similar ID$_{50}$ values. A serum-free medium supplemented with 1 μM scyphostatin or 5 μM PPMP (~ID$_{50}$ from the microscopic assay in Fig. 5 B) was used to obtain a reproducible intraerythrocytic development. As shown in Fig. 6, in an inhibitor-free control culture medium containing vehicle solvent (0.1% DMSO), the parasite developed normally and entered the next cycle at 52 h with ~5.6% parasitemia of newly formed ring (lane 1). When 1 μM scyphostatin was added at the initial ring stage (0 h), parasite cells devo-
Figure 5. Parasite growth inhibition by scyphostatin. (A) In vitro susceptibility of parasite lines to scyphostatin in a standard medium. The values are expressed as the percentage of the [3H]hypoxanthine incorporation into parasites treated with scyphostatin over those without treatment. The DMSO content in the assay media did not exceed 0.6%, which did not show any effect on the [3H]hypoxanthine incorporation into parasites treated with scyphostatin over those without treatment. The mean values of triplicates from two independent experiments were used for each plot. Filled circles, 3D7; filled triangle, Honduras-1; filled squares, FCR3. (B) In vitro susceptibility of Honduras-1 line to scyphostatin (circles) or PPMP (triangles) in a serum-free medium was examined through either [3H]hypoxanthine incorporation assay (filled symbols) or microscopic assay (open symbols).

Discussion

In this study, we identified a plasmodial gene (named PfNSM) encoding a neutral SMase. As far as we know, this is the first report in the molecular cloning of a protozoan SMase. When GST-PfNSMase, a fusion protein of the PfNSM product with GST, was expressed in E. coli, the cells produced SMase activity liberating phosphocholine from SM. Enzyme properties of GST-PfNSMase are consistent in various respects with those of SMase detected in P. falciparum-infected erythrocytes and isolated parasites. They require Mg2+ and anionic phospholipids for SMase activity in vitro, and are efficiently inhibited by scyphostatin (27; Fig. 4). The optimum pH of the activity is around pH 7.5, and the apparent \( K_m \) for SM is 50–100 \( \mu M \). Further characterization of GST-PfNSMase expressed in E. coli has revealed that the plasmodial SMase is capable of hydrolyzing LCPLs such as lysoPtdCho and lysoPAF in vitro (Fig. 3). The membrane fraction from P. falciparum parasites also retained this LCPL-PLC activity (data not shown). Henceforth, we refer to the PfNSM product as a plasmodial SM/LCPL-PLC.

LCPL-PLC activity of the plasmodial SM/LCPL-PLC was hardly detected in the presence of 0.1% Triton X-100, although the same enzyme source showed a high activity of SMase in the presence of the detergent. It is currently unknown as to why PLC activities to different substrates by the same enzyme are differently affected by detergents. Because both activities of SMase and LCPL-PLC that are associated with the protein encoded in the PfNSM are similarly inhibited by scyphostatin (Fig. 4), it is unlikely that this enzyme has two catalytic sites and each of them mediates one of two reactions. Efficient hydrolysis of lysoPtdCho and lysoPAF under detergent-free condition was also observed in a mammalian SMase (nSMase-1; reference 19). Not only the plasmodial SM/LCPL-PLC but also bacterial SMases and a mammalian SMase (nSMase-1) are capable of hydrolyzing lysoPtdCho (19, 41; Fig. 3 A). However, the ratios of lysoPtdCho–PLC activity determined under detergent-free conditions to SMase activity determined under the mixed micelle conditions are 0.5 or more for the plasmodial SM/LCPL-PLC and mammalian nSMase-1, but of trophozoite into schizont. Interestingly, the time for scyphostatin to start exerting the effect on the intraerythrocytic development is consistent with the time to start transcribing the PfNSM (Figs. 2 C and 6).

Similar to scyphostatin, PPMP impaired the stage progression from trophozoite to schizont, though, in this culture condition, the period PPMP exerts its effect was slightly broader than previously reported (7). The parasitemia of newly formed ring was severely affected when PPMP was added from 24–36 h (lanes 5, 7, 9, and 11). Unlike scyphostatin, the typical hemozoin formation was not observed in parasitized erythrocytes upon the addition of PPMP at ring stage (0 h; lane 3). These results imply that PPMP impairs the stage progression from ring to trophozoite as well.

Addition of scyphostatin at the mid- and late-trophozoite stages (28 and 32 h) resulted in an increase in the parasitemia of newly formed rings to 1–3% (lanes 6 and 8). Conversely, when added at the schizont (36 h) and segmented schizont (40 h) stages, the parasitemia of rings at 52 h reached the level comparable to that of the inhibitor-free control (lanes 10 and 12). These results indicate that 1 \( \mu M \) scyphostatin has no or little effect on the stage progression from ring to trophozoite as well as that from schizont to the next ring stage, but impaired specifically the maturation of trophozoites, but could not develop to schizonts, exhibiting a slightly bigger but less stained trophozoite-like morphology. These trophozoite-like structures neither developed further nor formed new ring stage parasites even after 52 h cultivation (lane 2). A similar effect on parasite morphology was observed when the scyphostatin was added at the early-trophozoite stage (24 h; lane 4). Addition of scyphostatin at the mid- and late-trophozoite stages (28 and 32 h) resulted in an increase in the parasitemia of newly formed rings to 1–3% (lanes 6 and 8). Conversely, when added at the schizont (36 h) and segmented schizont (40 h) stages, the parasitemia of rings at 52 h reached the level comparable to that of the inhibitor-free control (lanes 10 and 12). These results indicate that 1 \( \mu M \) scyphostatin has no or little effect on the stage progression from ring to trophozoite as well as that from schizont to the next ring stage, but impaired specifically the maturation of trophozoites into schizont. Interestingly, the time for scyphostatin to start exerting the effect on the intraerythrocytic development is consistent with the time to start transcribing the PfNSM (Figs. 2 C and 6).

Similar to scyphostatin, PPMP impaired the stage progression from trophozoite to schizont, though, in this culture condition, the period PPMP exerts its effect was slightly broader than previously reported (7). The parasitemia of newly formed ring was severely affected when PPMP was added from 24–36 h (lanes 5, 7, 9, and 11). Unlike scyphostatin, the typical hemozoin formation was not observed in parasitized erythrocytes upon the addition of PPMP at ring stage (0 h; lane 3). These results imply that PPMP impairs the stage progression from ring to trophozoite as well.

Discussion

In this study, we identified a plasmodial gene (named PfNSM) encoding a neutral SMase. As far as we know, this is the first report in the molecular cloning of a protozoan SMase. When GST-PfNSMase, a fusion protein of the PfNSM product with GST, was expressed in E. coli, the cells produced SMase activity liberating phosphocholine from SM. Enzyme properties of GST-PfNSMase are consistent in various respects with those of SMase detected in P. falciparum-infected erythrocytes and isolated parasites. They require Mg2+ and anionic phospholipids for SMase activity in vitro, and are efficiently inhibited by scyphostatin (27; Fig. 4). The optimum pH of the activity is around pH 7.5, and the apparent \( K_m \) for SM is 50–100 \( \mu M \). Further characterization of GST-PfNSMase expressed in E. coli has revealed that the plasmodial SMase is capable of hydrolyzing LCPLs such as lysoPtdCho and lysoPAF in vitro (Fig. 3). The membrane fraction from P. falciparum parasites also retained this LCPL-PLC activity (data not shown). Henceforth, we refer to the PfNSM product as a plasmodial SM/LCPL-PLC.

LCPL-PLC activity of the plasmodial SM/LCPL-PLC was hardly detected in the presence of 0.1% Triton X-100, although the same enzyme source showed a high activity of SMase in the presence of the detergent. It is currently unknown as to why PLC activities to different substrates by the same enzyme are differently affected by detergents. Because both activities of SMase and LCPL-PLC that are associated with the protein encoded in the PfNSM are similarly inhibited by scyphostatin (Fig. 4), it is unlikely that this enzyme has two catalytic sites and each of them mediates one of two reactions. Efficient hydrolysis of lysoPtdCho and lysoPAF under detergent-free condition was also observed in a mammalian SMase (nSMase-1; reference 19). Not only the plasmodial SM/LCPL-PLC but also bacterial SMases and a mammalian SMase (nSMase-1) are capable of hydrolyzing lysoPtdCho (19, 41; Fig. 3 A). However, the ratios of lysoPtdCho–PLC activity determined under detergent-free conditions to SMase activity determined under the mixed micelle conditions are 0.5 or more for the plasmodial SM/LCPL-PLC and mammalian nSMase-1, but of trophozoites, but could not develop to schizonts, exhibiting a slightly bigger but less stained trophozoite-like morphology. These trophozoite-like structures neither developed further nor formed new ring stage parasites even after 52 h cultivation (lane 2). A similar effect on parasite morphology was observed when the scyphostatin was added at the early-trophozoite stage (24 h; lane 4). Addition of scyphostatin at the mid- and late-trophozoite stages (28 and 32 h) resulted in an increase in the parasitemia of newly formed rings to 1–3% (lanes 6 and 8). Conversely, when added at the schizont (36 h) and segmented schizont (40 h) stages, the parasitemia of rings at 52 h reached the level comparable to that of the inhibitor-free control (lanes 10 and 12). These results indicate that 1 \( \mu M \) scyphostatin has no or little effect on the stage progression from ring to trophozoite as well as that from schizont to the next ring stage, but impaired specifically the maturation
The ID$_{50}$ values of scyphostatin and PPMP for the parasite growth in a serum-free medium determined by the [H]hypoxanthine incorporation assay are 1.2 and 3.5 μM, respectively, whereas by microscopic assay those of scyphostatin and PPMP are 0.2 and 0.6 μM, respectively (Fig. 5 B). In the microscopic analysis, parasitized erythrocyte exhibiting an abnormal trophozoite-like morphology and a tiny ring- or early trophozoite-like morphology observed in the culture treated with scyphostatin (at 52 h in lane 2, Fig. 6) and PPMP (at 52 h in lane 3, Fig. 6), respectively,
were evident at 0.1–1 μM scyphostatin and 0.3–3 μM PPMP. These morphologies, however, could not be observed at 96 h with concentrations >0.1 μM scyphostatin and >2 μM PPMP in a similar assay condition (data not shown). The parasites exhibiting such abnormal morphologies might be committed to cell death, but still retain metabolic activity with respect to hypoxanthine incorporation into nucleic acid, thereby giving differences in ID₅₀ values depending on assay methods (Fig. 5 B).

Transcription of PfNSM is initiated from the young trophozoite stage and becomes most active in segmented schizonts (Fig. 2 C), and scyphostatin impairs the maturation of trophozoite into schizont during the intraerythrocytic development of P. falciparum (Fig. 6). This good correlation of the time for the PfNSM transcription and the developmental stage on which scyphostatin exerts its effect leads us to suggest that the inhibition of the intraerythrocytic development of the parasite results from the inhibition of the plasmodial SM/LCPL-PLC activity. Lauer et al. (7) indicated that PPMP inhibits SM synthesize activity associated with P. falciparum cells, and also inhibits proliferation of the parasite in vitro. PPMP does not inhibit plasmodial SM/LCPL-PLC activity, while scyphostatin does not inhibit SM synthesize activity, indicating that the target enzymes of the two inhibitors differ (27). The stage progression influenced by scyphostatin overlaps with that of PPMP (progression from trophozoite to schizont), although the stage influenced by scyphostatin is narrower. Parasites treated with both inhibitors at the trophozoite stage show similar morphological changes (Fig. 6). We assume that a certain functional linkage to maintain the normal intraerythrocytic development at least in the maturation of trophozoite into schizont of P. falciparum might exist between SM synthesize, the target of PPMP, and SM/LCPL-PLC, the target of scyphostatin. The knowledge obtained in this study together with previous studies (7, 27) would emphasize the importance of the enzymes involved in SM metabolism as rational targets for malaria chemotherapy, although the development of specific inhibitors to plasmodial enzymes is needed in this direction. Interestingly, the ID₅₀ value of scyphostatin to bovine brain SMase is ~5-fold higher than that of plasmodial SMase (Fig. 4), indicating the possibility that derivation of scyphostatin leads to more selective or specific inhibitors to plasmodial SM/LCPL-PLC.

Although physiological and pathological roles of the SM/LCPL-PLC in P. falciparum cells remain unclear, there are several possible roles. First, as we have been proposing (reference 27, and above), the plasmodial SM/LCPL-PLC might degrade host-derived SM to supply the parasite with ceramide, which would modulate the cell cycle progression of intraerythrocytic parasites and/or would be used for resynthesis of SM within parasitized erythrocytes. In this regard, we have proposed the possibility that the host-cell SM is accessible to the plasmodial SM/LCPL-PLC through the tubovesicular membrane structure (27). This proposal is supported by the recent finding demonstrated by Lauer et al. (42) that degradation of externally supplied sphingomyelin analogs in parasitized-erythrocytes is inhibited when cells were treated with PPMP which impaired the formation of the tubovesicular membrane structure. Note that the stage-specific transcription of PfNSM gene correlates well with the C₁₂-NBD-SM hydrolyzing activity levels (this study, and reference 42). Second, the plasmodial SM/LCPL-PLC might degrade host-derived lysoPtdCho to supply the parasites with phosphocholine and/or monoaeglycylcerol for their efficient intraerythrocytic growth since lysoPtdCho is abundant in the human plasma, especially in forms associated with lipoproteins (43, 44). Third, the plasmodial SM/LCPL-PLC might be implicated to detoxify LCPLs. It has been recently shown that human lipoproteins treated with bee venom phospholipase A₂ are highly toxic to the in vitro culture of P. falciparum (45). As the most abundant type of phospholipids associated with lipoproteins is PtdCho (43, 44), treatment of lipoproteins with phospholipase A₂ is predicted to enhance greatly the level of lysoPtdCho. If so, the plasmodial SM/LCPL-PLC could be involved in the detoxification of potentially harmful lysoPtdCho. Finally, a previous study showed that the level of plasma lysoPAF in patients with severe malaria is reduced to ~10% from the normal level, and suggested that the reduction of the plasma lysoPAF level was due to the increased production of PAF in malaria patients (46). Our finding in this study raises an alternative, but not mutually exclusive, explanation that an enhanced degradation of lysoPAF through plasmodial SM/LCPLs-PLC results to a decrease in the plasma lysoPAF level.

Success in the identification of the gene for P. falciparum SM/LCPL-PLC and production of the plasmodial SM/LCPL-PLC in E. coli as a recombinant protein could facilitate elucidation of the physiological functions of this enzyme and create invaluable tools that can be exploited to localize this enzyme within parasitized erythrocytes, to study for the regulation of gene expression, and to perform transfection experiments.

We thank Drs. Thomas E. Wellem and Masatsugu Kimura for providing the parasite lines of P. falciparum, Dr. Debopam Chakrabarti for providing PF1350C, a P. falciparum EST clone, Mr. Emmanuel S. Palacpac for preparing figures, and Sankyo Co. for scyphostatin. This work was supported in part by Grant-in-Aids from Ministry of Education, Culture, Sports, Science and Technology. N.M.Q. Palacpac is a recipient of the Japanese Society for the Promotion of Science Post-Doctoral Fellowship.

Submitted: 27 April 2001
Revised: 19 October 2001
Accepted: 6 November 2001

References
1. van Deenen, L.L.M., and J. de Gier. 1974. Lipids of the red cell membrane. In The Red Blood Cell. D.M. Sargenpor, ed. Academic Press, New York. 147–211.
2. Holz, G.G., Jr. 1977. Lipids and the malaria parasite. Bull. World Health Organ. 55:237–248.
3. Sherman, I.W. 1979. Biochemistry of Plasmodium (malarial parasites). Microbiol. Rev. 43:453–495.

32 P. falciparum Sphingomyelin/Lysocholinephospholipids-Phospholipase C
37. Nielsen, H., J. Engelbrecht, S. Brunak, and G. von Heijne. 1997. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. *Protein Eng.* 10:1–6.

38. Kumar, S., K. Tamura, I.B. Jakobsen, and M. Nei. 2001. MEGA2: Molecular evolutionary genetics analysis software. *Bioinformatics.* In press.

39. Nara, F., M. Tanaka, T. Hosoya, K. Suzuki-Konagai, and T. Ogita. 1999. Scyphostatin, a neutral sphingomyelinase inhibitor from a Discomycete, *Trichopeziza mollissima*: taxonomy of the producing organism, fermentation, isolation, and physico-chemical properties. *J. Antibiot.* 52:525–530.

40. Nara, F., M. Tanaka, S. Masuda-Inoue, Y. Yamasato, H. Doi-Yoshioka, K. Suzuki-Konagai, S. Kumakura, and T. Ogita. 1999. Biological activity of scyphostatin, a neutral sphingomyelinase inhibitor from a Discomycete, *Trichopeziza mollissima*. *J. Antibiot.* 52:531–535.

41. Tomita, M., R. Taguchi, and H. Ikezawa. 1982. Molecular properties and kinetic studies on sphingomyelinase of *Bacillus cereus*. *Biochim. Biophys. Acta.* 704:90–99.

42. Lauer, S. A., S. Chatterjee, and K. Haldar. 2001. Uptake and hydrolysis of sphingomyelin analogues in *Plasmodium falciparum*-infected red cells. *Mol. Biochem. Parasitol.* 115:275–281.

43. Wood, P., K. Imaichi, J. Knowles, G. Michaels, and L. KinSELL. 1964. The lipid composition of human plasma chylomicrons. *J. Lipid Res.* 5:225–231.

44. Myher, J.J., A. Kuksis, and S. Pind. 1989. Molecular species of glycerophospholipids and sphingomyelins of human plasma: comparison to red blood cells. *Lipids.* 24:408–418.

45. Deregnaucourt, C., and J. Schrevel. 2000. Bee venom phospholipase A₂ induces stage-specific growth arrest of the intraerythrocytic *Plasmodium falciparum* via modification of human serum components. *J. Biol. Chem.* 275:39973–39980.

46. Davis, T.M., T.Q. Binh, N. van Phuong, M. Sturm, A. St John, J.R. Dyer, and T.K. Anh. 1995. The metabolism of platelet-activating factor in severe and cerebral malaria. *J. Infect.* 31:181–188.

47. Thompson, J.D., D.G. Higgins, and T.J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res.* 22:4673–4680.

48. Kurokawa, K., Y. Hasegawa, K. Kawashima, T. Okamura, T. Takagi, and T. Yasunaga. 1999. GeneAlign: Java application software for multiple sequence alignment editor. *Genome Inform.* 10:208–209.